Figure 1. CAR-T Therapy
Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) is an immunotherapy for chimeric antigen receptor T cells. The principle is that human T cells are modified by genetic engineering to express chimeric antigen receptor (CAR), that is, antibodies that recognize tumor cell surface antigens are connected with signal molecules needed to activate T cells, so as to enhance the specific killing of T cells to tumors. When CAR-T is infused back to the patient to bind to the target antigen on the surface of tumor cells, it activates the proliferation of CAR-T cells and the ability to kill tumor cells. CAR-T cells need to complete preclinical research before clinical trials. Creative Proteomics can provide CAR-T cell preparation services, preclinical in vitro cell experiments, preclinical in vivo verification experiments and other services.
A. Design of scFv and CAR frame
B. Packaging purification of CAR lentivirus
C. T cell infection and value-added clustering detection
D. Target cell killing test in vitro
E. In vivo killing experiment of model animals
CAR-T preclinical service flow
Mature and reliable tumor CAR-T cell experimental analysis platform: rich project experience, participate in major projects, publish high-level cooperation results.
The analysis contents and methods based on high-quality data analysis, pre-research and verification are indeed mature and feasible..
Creative Proteomics leads a rich team that uses the most rigorous experimental solutions and internationally recognized CAR-T cell experimental analysis techniques to obtain your customized information. Use the most accurate experimental results to help you better carry out tumor-related scientific research.
Please contact us to find out how we can help you achieve the next research breakthrough.